850429-50-4

Basic information

• Product Name: (TETRAHYDRO-PYRAN-4-YL)-ACETONITRILE
• Synonyms: 4-CYANOMETHYLTETRAHYDROPYRAN;2-(TETRAHYDRO-2H-PYRAN-4-YL)ACETONITRILE;TETRAHYDRO-2H-PYRAN-4-YLACETONITRILE;(TETRAHYDRO-PYRAN-4-YL)-ACETONITRILE;Tetrahydro-2H-pyran-4-ylacetonitrile 95%;2-(Tetrahydro-2H-pyran-4-yl)acetonitrile ,95%;2H-Pyran-4-acetonitrile, tetrahydro-;Tetrahydro-2H-pyran-4-ylacetonitrile95%
• CAS NO: 850429-50-4
• Molecular Formula: C₇H₁₁NO
• Molecular Weight: 125.17
• EINECS: 256-896-0
• Product Categories: blocks;Carboxes;Heterocycles
• Mol File: 850429-50-4.mol

Chemical Properties

• Boiling Point: 83-85/0.5mm
• Flash Point: 101.8℃
• Appearance: /
• Density: 0.974
• Vapor Pressure: 0.03mmHg at 25°C
• Refractive Index: 1.441
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (TETRAHYDRO-PYRAN-4-YL)-ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (TETRAHYDRO-PYRAN-4-YL)-ACETONITRILE(850429-50-4)
• EPA Substance Registry System: (TETRAHYDRO-PYRAN-4-YL)-ACETONITRILE(850429-50-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 850429-50-4(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

InChI:InChI=1/C7H11NO/c8-4-1-7-2-5-9-6-3-7/h7H,1-3,5-6H2

Upstream product

• 125552-89-8 4-(bromomethyl)tetrahydro-2H-pyran 
• 151-50-8 potassium cyanide 
• 1624363-23-0 3-azido-2-methylbut-3-en-2-ol 
• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 1768-64-5 4-chlorotetrahydro-2H-pyran 
• 204651-40-1 2-(tetrahydro-4H-pyran-4-ylidene)acetonitrile 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 

Downstream Products

• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 65412-03-5 4-(2-aminoethyl)tetrahydropyran 

Relevant articles and documents

TREATMENT OF CD151 RELATED DISORDERS

The present invention relates to a method of treating a condition in a human related to CD151 the method comprising administering a therapeutically effective amount of a compound of Formula (I):

METHOD OF TREATMENT OF CYTOMEGALOVIRUS

The present invention relates to a method of prophylaxis or treatment of Cytomegalovirus infection in a subject the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

METHODS OF PROPHYLAXIS AND TREATMENT OF CORONA VIRUS

The present invention relates to a method of prophylaxis or treatment of Corona virus infection in a subject the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

TREATMENT OF VETERINARY CONDITIONS ASSOCIATED WITH CD151

The present invention relates to a method of treating a condition related to CD151 in a non-human animal, the method comprising administering a therapeutically effective amount of a compound of Formula (I): Formula (I)

Radical cyanomethylation via vinyl azide cascade-fragmentation

Herein, a novel methodology for radical cyanomethylation is described. The process is initiated by radical addition to the vinyl azide reagent 3-azido-2-methylbut-3-en-2-ol which triggers a cascade-fragmentation mechanism driven by the loss of dinitrogen and the stabilised 2-hydroxypropyl radical, ultimately effecting cyanomethylation. Cyanomethyl groups can be efficiently introduced into a range of substrates via trapping of α-carbonyl, heterobenzylic, alkyl, sulfonyl and aryl radicals, generated from a variety of functional groups under both photoredox catalysis and non-catalytic conditions. The value of this approach is exemplified by the late-stage cyanomethylation of pharmaceuticals.

Corresponding amine nitrile and method of manufacturing thereof

The invention relates to a manufacturing method of nitrile. Compared with the prior art, the manufacturing method has the characteristics of significantly reduced using amount of an ammonia source, low environmental pressure, low energy consumption, low production cost, high purity and yield of a nitrile product and the like, and nitrile with a more complex structure can be obtained. The invention also relates to a method for manufacturing corresponding amine from nitrile.

A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor

Recently, a novel negative allosteric modulator (NAM) of the D2-like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.

Synthetic method of 4-(2-aminoethyl) tetrahydropyrane

The invention belongs to the technical field of chemical medicine intermediate synthesis, and particularly relates to a synthetic method of medicine Bevenopran intermediate 4-(2-aminoethyl) tetrahydropyrane. The method comprises the following steps that (1) 4-chloro amylene oxide and methyl cyanoacetate take a reaction to obtain 2-cyano-2-(tetralin-4-pyranyl) methyl acetate; (2) the 2-cyano-2-(tetralin-4-pyranyl) methyl acetate is degreased to obtain (tetralin-4-pyranyl)-acetonitrile; (3) the (tetralin-4-pyranyl)-acetonitrile C takes a hydrogenation reaction to obtain 4-(2- aminoethyl) tetrahydropyrane. The method has the advantages that the 4-chloro amylene oxide and the methyl cyanoacetate are used as raw materials; the reaction time of the method is short; the cost is low; the raw materials are easy to obtain; no rank poison control or unstable chemical raw materials exist; safety and effectiveness are realized; the yield is high; the impurities are few.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to the pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious disease, disorders, or conditions in which protein kinase activity is implicated. More particularly, the present invention relates to a compound of Formula I.